Llwytho...
Evaluating ivosidenib for the treatment of relapsed/refractory AML: design, development, and place in therapy
Improvements in the last decade in understanding the molecular mechanisms underlying acute myeloid leukemia (AML) have emphasized that treatment regimens should be personalized with agents that can selectively target genetic abnormalities if present. Neomorphic mutations in isoform 1 of isocitrate d...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Onco Targets Ther |
|---|---|
| Prif Awduron: | , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Dove Medical Press
2018
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6314316/ https://ncbi.nlm.nih.gov/pubmed/30643428 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S182443 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|